Article

Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.

Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; P_FDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; P_FDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.

Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.

Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source

Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.

Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; P_FDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; P_FDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.

Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.

Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source

Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.

Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; P_FDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; P_FDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.

Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.

Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source

Key clinical point: The presence of type 2 diabetes (T2D) and smoking history increased the risk for psoriatic arthritis (PsA) in patients with psoriasis; however, T2D seemed to have a greater impact than smoking history in increasing incidence rate of PsA.

Major finding: The risk for PsA was significantly higher in patients with psoriasis who did vs did not have T2D (hazard ratio [HR] 1.11; 95% CI 1.03-1.20) and in those with vs without smoking history (HR 1.11; 95% CI 1.06-1.17). However, the risk was not significant in patients with psoriasis and T2D with vs without smoking history (HR 1.05; 95% CI 0.92-1.20).

Study details: This retrospective cohort study included patients with psoriasis with or without T2D (n = 42,315 each), those with or without smoking history (n = 74,046 each), and those with T2D with or without smoking history (n = 13,065 each).

Disclosures: This study was funded by the Chung Shan Medical University Hospital research project. The authors declared no conflicts of interest.

Source: Huo A-P, Liao P-L, Leong P-Y, Wei JC-C. From psoriasis to psoriatic arthritis: Epidemiological insights from a retrospective cohort study of 74,046 patients. Front Med. 2024;11:1419722 (June 26). Doi: 10.3389/fmed.2024.1419722 Source

Key clinical point: The presence of type 2 diabetes (T2D) and smoking history increased the risk for psoriatic arthritis (PsA) in patients with psoriasis; however, T2D seemed to have a greater impact than smoking history in increasing incidence rate of PsA.

Major finding: The risk for PsA was significantly higher in patients with psoriasis who did vs did not have T2D (hazard ratio [HR] 1.11; 95% CI 1.03-1.20) and in those with vs without smoking history (HR 1.11; 95% CI 1.06-1.17). However, the risk was not significant in patients with psoriasis and T2D with vs without smoking history (HR 1.05; 95% CI 0.92-1.20).

Study details: This retrospective cohort study included patients with psoriasis with or without T2D (n = 42,315 each), those with or without smoking history (n = 74,046 each), and those with T2D with or without smoking history (n = 13,065 each).

Disclosures: This study was funded by the Chung Shan Medical University Hospital research project. The authors declared no conflicts of interest.

Source: Huo A-P, Liao P-L, Leong P-Y, Wei JC-C. From psoriasis to psoriatic arthritis: Epidemiological insights from a retrospective cohort study of 74,046 patients. Front Med. 2024;11:1419722 (June 26). Doi: 10.3389/fmed.2024.1419722 Source

Key clinical point: The presence of type 2 diabetes (T2D) and smoking history increased the risk for psoriatic arthritis (PsA) in patients with psoriasis; however, T2D seemed to have a greater impact than smoking history in increasing incidence rate of PsA.

Major finding: The risk for PsA was significantly higher in patients with psoriasis who did vs did not have T2D (hazard ratio [HR] 1.11; 95% CI 1.03-1.20) and in those with vs without smoking history (HR 1.11; 95% CI 1.06-1.17). However, the risk was not significant in patients with psoriasis and T2D with vs without smoking history (HR 1.05; 95% CI 0.92-1.20).

Study details: This retrospective cohort study included patients with psoriasis with or without T2D (n = 42,315 each), those with or without smoking history (n = 74,046 each), and those with T2D with or without smoking history (n = 13,065 each).

Disclosures: This study was funded by the Chung Shan Medical University Hospital research project. The authors declared no conflicts of interest.

Source: Huo A-P, Liao P-L, Leong P-Y, Wei JC-C. From psoriasis to psoriatic arthritis: Epidemiological insights from a retrospective cohort study of 74,046 patients. Front Med. 2024;11:1419722 (June 26). Doi: 10.3389/fmed.2024.1419722 Source

Key clinical point: In individuals with vs without psoriatic arthritis (PsA), periodontitis was highly prevalent and negatively affected oral Health-Related Quality of Life (HRQOL).

Major finding: Individuals with vs without PsA were 2.67 times more likely to develop periodontitis (prevalence 57.0% vs 33.1%; odds ratio 2.67; P < .001), which was significantly associated with worsened oral HRQOL (odds ratio 1.92; P < .001). The mean Oral Impacts on Daily Performance scores, indicative of oral HRQOL, were also higher in individuals with vs without PsA (P < .001).

Study details: This case-control study included 86 individuals with PsA, 210 individuals with psoriasis, and 359 control individuals without psoriasis, all age 35-65 years and having ≥ 14 teeth.

Disclosures: This study was supported by the National Council for Scientific and Technological Development - CNPq, Brazil. The authors declared no conflicts of interest.

Source: Costa AA, Cota LOM, Esteves Lima RP, et al. The association between periodontitis and the impact of oral health on the quality of life of individuals with psoriasis and psoriatic arthritis. PLoS One. 2024;19(6):e0301158 (June 25). Doi: 10.1371/journal.pone.0301158 Source

Key clinical point: In individuals with vs without psoriatic arthritis (PsA), periodontitis was highly prevalent and negatively affected oral Health-Related Quality of Life (HRQOL).

Major finding: Individuals with vs without PsA were 2.67 times more likely to develop periodontitis (prevalence 57.0% vs 33.1%; odds ratio 2.67; P < .001), which was significantly associated with worsened oral HRQOL (odds ratio 1.92; P < .001). The mean Oral Impacts on Daily Performance scores, indicative of oral HRQOL, were also higher in individuals with vs without PsA (P < .001).

Study details: This case-control study included 86 individuals with PsA, 210 individuals with psoriasis, and 359 control individuals without psoriasis, all age 35-65 years and having ≥ 14 teeth.

Disclosures: This study was supported by the National Council for Scientific and Technological Development - CNPq, Brazil. The authors declared no conflicts of interest.

Source: Costa AA, Cota LOM, Esteves Lima RP, et al. The association between periodontitis and the impact of oral health on the quality of life of individuals with psoriasis and psoriatic arthritis. PLoS One. 2024;19(6):e0301158 (June 25). Doi: 10.1371/journal.pone.0301158 Source

Key clinical point: In individuals with vs without psoriatic arthritis (PsA), periodontitis was highly prevalent and negatively affected oral Health-Related Quality of Life (HRQOL).

Major finding: Individuals with vs without PsA were 2.67 times more likely to develop periodontitis (prevalence 57.0% vs 33.1%; odds ratio 2.67; P < .001), which was significantly associated with worsened oral HRQOL (odds ratio 1.92; P < .001). The mean Oral Impacts on Daily Performance scores, indicative of oral HRQOL, were also higher in individuals with vs without PsA (P < .001).

Study details: This case-control study included 86 individuals with PsA, 210 individuals with psoriasis, and 359 control individuals without psoriasis, all age 35-65 years and having ≥ 14 teeth.

Disclosures: This study was supported by the National Council for Scientific and Technological Development - CNPq, Brazil. The authors declared no conflicts of interest.

Source: Costa AA, Cota LOM, Esteves Lima RP, et al. The association between periodontitis and the impact of oral health on the quality of life of individuals with psoriasis and psoriatic arthritis. PLoS One. 2024;19(6):e0301158 (June 25). Doi: 10.1371/journal.pone.0301158 Source

Key clinical point: Around 25% patients with psoriatic arthritis (PsA) had a sedentary lifestyle (< 90 min of physical activity per week), with lack of physical activity associated with pain, worsened clinical activity, functionality, and disease impact.

Major finding: Overall, 25.9% of patients had a sedentary lifestyle. Patients with a sedentary vs non-sedentary lifestyle had more enthesitis, fatigue, higher disease activity, greater disease impact, and lower functionality (all P < .05). Sedentary lifestyle was also associated with increased risk for pain (odds ratio 1.5; P < .001).

Study details: This cross-sectional study included 232 patients with PsA aged 18-69 years with no radiographic damage or respiratory or cardiac diseases that limit physical activity.

Disclosures: This study did not receive any financial support. The authors declared no conflicts of interest. During the review, the reviewer declared a shared affiliation, with no collaboration, of the lead author to the handling editor.

Source: Toledano E, Chacón CC, Compán O, et al. Analysis of physical activity in psoriatic arthritis: Relationship with clinical and analytical parameters and comorbidity—description of the sedentary patient. Front Med. 2024;11:1385842 (June 23). Doi: 10.3389/fmed.2024.1385842 Source

Key clinical point: Around 25% patients with psoriatic arthritis (PsA) had a sedentary lifestyle (< 90 min of physical activity per week), with lack of physical activity associated with pain, worsened clinical activity, functionality, and disease impact.

Major finding: Overall, 25.9% of patients had a sedentary lifestyle. Patients with a sedentary vs non-sedentary lifestyle had more enthesitis, fatigue, higher disease activity, greater disease impact, and lower functionality (all P < .05). Sedentary lifestyle was also associated with increased risk for pain (odds ratio 1.5; P < .001).

Study details: This cross-sectional study included 232 patients with PsA aged 18-69 years with no radiographic damage or respiratory or cardiac diseases that limit physical activity.

Disclosures: This study did not receive any financial support. The authors declared no conflicts of interest. During the review, the reviewer declared a shared affiliation, with no collaboration, of the lead author to the handling editor.

Source: Toledano E, Chacón CC, Compán O, et al. Analysis of physical activity in psoriatic arthritis: Relationship with clinical and analytical parameters and comorbidity—description of the sedentary patient. Front Med. 2024;11:1385842 (June 23). Doi: 10.3389/fmed.2024.1385842 Source

Key clinical point: Around 25% patients with psoriatic arthritis (PsA) had a sedentary lifestyle (< 90 min of physical activity per week), with lack of physical activity associated with pain, worsened clinical activity, functionality, and disease impact.

Major finding: Overall, 25.9% of patients had a sedentary lifestyle. Patients with a sedentary vs non-sedentary lifestyle had more enthesitis, fatigue, higher disease activity, greater disease impact, and lower functionality (all P < .05). Sedentary lifestyle was also associated with increased risk for pain (odds ratio 1.5; P < .001).

Study details: This cross-sectional study included 232 patients with PsA aged 18-69 years with no radiographic damage or respiratory or cardiac diseases that limit physical activity.

Disclosures: This study did not receive any financial support. The authors declared no conflicts of interest. During the review, the reviewer declared a shared affiliation, with no collaboration, of the lead author to the handling editor.

Source: Toledano E, Chacón CC, Compán O, et al. Analysis of physical activity in psoriatic arthritis: Relationship with clinical and analytical parameters and comorbidity—description of the sedentary patient. Front Med. 2024;11:1385842 (June 23). Doi: 10.3389/fmed.2024.1385842 Source

Key clinical point: A genetic variant of the IL-13 gene that was designed to mimic the therapeutic effects of interleukin-13 (IL-13) inhibition was associated with an increased risk for psoriatic arthritis (PsA).

Major finding: IL-13 inhibition, genetically mimicked using an IL-13 gene variant was associated with an increased risk for PsA (odds ratio 37.39; P = 1.64×10^-9).

Study details: This two-sample Mendelian randomization study analyzed the data of 563,946 individuals with exposure to IL-13 inhibition while the genetic outcomes were assessed in 3609 patients with PsA and 9192 control individuals without PsA.

Disclosures: This study was supported by the National Institute for Health Research Manchester Biomedical Research Centre, UK. Three authors declared receiving grants, consulting fees, speaker fees, honoraria, or travel support from various sources unrelated to this study. Other authors declared no conflicts of interest.

Source: Zhao SS, Hyrich K, Yiu Z, et al. Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study. Arthritis Rheumatol. 2024 (July 8). Doi: 10.1002/art.42942 Source

Key clinical point: A genetic variant of the IL-13 gene that was designed to mimic the therapeutic effects of interleukin-13 (IL-13) inhibition was associated with an increased risk for psoriatic arthritis (PsA).

Major finding: IL-13 inhibition, genetically mimicked using an IL-13 gene variant was associated with an increased risk for PsA (odds ratio 37.39; P = 1.64×10^-9).

Study details: This two-sample Mendelian randomization study analyzed the data of 563,946 individuals with exposure to IL-13 inhibition while the genetic outcomes were assessed in 3609 patients with PsA and 9192 control individuals without PsA.

Disclosures: This study was supported by the National Institute for Health Research Manchester Biomedical Research Centre, UK. Three authors declared receiving grants, consulting fees, speaker fees, honoraria, or travel support from various sources unrelated to this study. Other authors declared no conflicts of interest.

Source: Zhao SS, Hyrich K, Yiu Z, et al. Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study. Arthritis Rheumatol. 2024 (July 8). Doi: 10.1002/art.42942 Source

Key clinical point: A genetic variant of the IL-13 gene that was designed to mimic the therapeutic effects of interleukin-13 (IL-13) inhibition was associated with an increased risk for psoriatic arthritis (PsA).

Major finding: IL-13 inhibition, genetically mimicked using an IL-13 gene variant was associated with an increased risk for PsA (odds ratio 37.39; P = 1.64×10^-9).

Study details: This two-sample Mendelian randomization study analyzed the data of 563,946 individuals with exposure to IL-13 inhibition while the genetic outcomes were assessed in 3609 patients with PsA and 9192 control individuals without PsA.

Disclosures: This study was supported by the National Institute for Health Research Manchester Biomedical Research Centre, UK. Three authors declared receiving grants, consulting fees, speaker fees, honoraria, or travel support from various sources unrelated to this study. Other authors declared no conflicts of interest.

Source: Zhao SS, Hyrich K, Yiu Z, et al. Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study. Arthritis Rheumatol. 2024 (July 8). Doi: 10.1002/art.42942 Source

Key clinical point: Multimorbidity was present in nearly 50% of patients with psoriatic arthritis (PsA) and significantly affected the physical aspects of their quality of life.

Major finding: Multimorbidity was observed in 50.2% patients, with cardiovascular diseases being the most prevalent comorbidity. Patients with vs without multimorbidity had worsened scores for various 36-Item Short Form Health Survey domains, including bodily pain (34.7 vs 47.5; P < .01), physical functioning (52.1 vs 63.1; P < .01), and ability to perform roles due to physical health problems (28.5 vs 42.8; P < .01).

Study details: This cross-sectional observational study included 267 patients with PsA, age > 18 years.

Disclosures: This study was supported by a grant from the National Centre for Research and Development, Warsaw, Poland. The authors declared no conflicts of interest.

Source: Biedroń G, Wilk M, Nowakowski J, et al. Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: A single centre cohort study. Rheumatol Int. Published online 2024;44:1435-1443. Doi: 10.1007/s00296-024-05632-2 Source

Key clinical point: Multimorbidity was present in nearly 50% of patients with psoriatic arthritis (PsA) and significantly affected the physical aspects of their quality of life.

Major finding: Multimorbidity was observed in 50.2% patients, with cardiovascular diseases being the most prevalent comorbidity. Patients with vs without multimorbidity had worsened scores for various 36-Item Short Form Health Survey domains, including bodily pain (34.7 vs 47.5; P < .01), physical functioning (52.1 vs 63.1; P < .01), and ability to perform roles due to physical health problems (28.5 vs 42.8; P < .01).

Study details: This cross-sectional observational study included 267 patients with PsA, age > 18 years.

Disclosures: This study was supported by a grant from the National Centre for Research and Development, Warsaw, Poland. The authors declared no conflicts of interest.

Source: Biedroń G, Wilk M, Nowakowski J, et al. Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: A single centre cohort study. Rheumatol Int. Published online 2024;44:1435-1443. Doi: 10.1007/s00296-024-05632-2 Source

Key clinical point: Multimorbidity was present in nearly 50% of patients with psoriatic arthritis (PsA) and significantly affected the physical aspects of their quality of life.

Major finding: Multimorbidity was observed in 50.2% patients, with cardiovascular diseases being the most prevalent comorbidity. Patients with vs without multimorbidity had worsened scores for various 36-Item Short Form Health Survey domains, including bodily pain (34.7 vs 47.5; P < .01), physical functioning (52.1 vs 63.1; P < .01), and ability to perform roles due to physical health problems (28.5 vs 42.8; P < .01).

Study details: This cross-sectional observational study included 267 patients with PsA, age > 18 years.

Disclosures: This study was supported by a grant from the National Centre for Research and Development, Warsaw, Poland. The authors declared no conflicts of interest.

Source: Biedroń G, Wilk M, Nowakowski J, et al. Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: A single centre cohort study. Rheumatol Int. Published online 2024;44:1435-1443. Doi: 10.1007/s00296-024-05632-2 Source

Key clinical point: The onset rate of psoriatic arthritis (PsA) in patients with psoriasis was lower with biologics than with methotrexate, with topical therapy being associated with the lowest rate.

Major finding: Treatment with biologics vs methotrexate significantly reduced the risk of developing PsA (adjusted hazard ratio [aHR] 0.46; 95% CI 0.35-0.62); however, biologics were associated with an increased risk of developing PsA when compared to topical therapy (aHR 2.16; 95% CI 1.44-3.24). Prior exposure to at least two biologics (odds ratio [OR] 6.09; P < .001) or methotrexate (OR 1.88; P = .026) was tied to increased PsA risk.

Study details: This retrospective cohort study included 58,671 patients with psoriasis treated with biologics, methotrexate, phototherapy, or topical therapy; patients who received phototherapy or topical therapy did not undergo any prior systemic treatment.

Disclosures: This study was supported by an educational grant from Janssen Pharmaceuticals. Alen Zabotti declared being an editorial board member of Rheumatology and Therapy. The other authors declared no conflicts of interest.

Source: Watad A, Zabotti A, Patt YS, et al. From psoriasis to psoriatic arthritis: Decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11:963-976 (June 7). Doi: 10.1007/s40744-024-00680-3 Source

Key clinical point: The onset rate of psoriatic arthritis (PsA) in patients with psoriasis was lower with biologics than with methotrexate, with topical therapy being associated with the lowest rate.

Major finding: Treatment with biologics vs methotrexate significantly reduced the risk of developing PsA (adjusted hazard ratio [aHR] 0.46; 95% CI 0.35-0.62); however, biologics were associated with an increased risk of developing PsA when compared to topical therapy (aHR 2.16; 95% CI 1.44-3.24). Prior exposure to at least two biologics (odds ratio [OR] 6.09; P < .001) or methotrexate (OR 1.88; P = .026) was tied to increased PsA risk.

Study details: This retrospective cohort study included 58,671 patients with psoriasis treated with biologics, methotrexate, phototherapy, or topical therapy; patients who received phototherapy or topical therapy did not undergo any prior systemic treatment.

Disclosures: This study was supported by an educational grant from Janssen Pharmaceuticals. Alen Zabotti declared being an editorial board member of Rheumatology and Therapy. The other authors declared no conflicts of interest.

Source: Watad A, Zabotti A, Patt YS, et al. From psoriasis to psoriatic arthritis: Decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11:963-976 (June 7). Doi: 10.1007/s40744-024-00680-3 Source

Key clinical point: The onset rate of psoriatic arthritis (PsA) in patients with psoriasis was lower with biologics than with methotrexate, with topical therapy being associated with the lowest rate.

Major finding: Treatment with biologics vs methotrexate significantly reduced the risk of developing PsA (adjusted hazard ratio [aHR] 0.46; 95% CI 0.35-0.62); however, biologics were associated with an increased risk of developing PsA when compared to topical therapy (aHR 2.16; 95% CI 1.44-3.24). Prior exposure to at least two biologics (odds ratio [OR] 6.09; P < .001) or methotrexate (OR 1.88; P = .026) was tied to increased PsA risk.

Study details: This retrospective cohort study included 58,671 patients with psoriasis treated with biologics, methotrexate, phototherapy, or topical therapy; patients who received phototherapy or topical therapy did not undergo any prior systemic treatment.

Disclosures: This study was supported by an educational grant from Janssen Pharmaceuticals. Alen Zabotti declared being an editorial board member of Rheumatology and Therapy. The other authors declared no conflicts of interest.

Source: Watad A, Zabotti A, Patt YS, et al. From psoriasis to psoriatic arthritis: Decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11:963-976 (June 7). Doi: 10.1007/s40744-024-00680-3 Source

Key clinical point: Patients with psoriatic arthritis (PsA) who did vs did not have Achilles tendon (AT) pain reported severe functional impairment and disability.

Major finding: Patients with PsA with vs without AT pain had significantly greater AT-related morning stiffness (90.9% vs 9.1%; P < .001), impaired AT function (median heel raise repetition rate 0.72 vs 1.24; P = .005), worse Psoriatic Arthritis Impact of Disease questionnaire score (mean 5.52 vs 3.38; P = .018), and pain on passive dorsiflexion (36.4% vs 0%; P = .011) and resisted plantarflexion (45.5% vs 0%; P = .003).

Study details: This cross-sectional, observational study included 22 patients with PsA with (n = 11) and without (n = 11) self-reported AT pain and 11 healthy individuals without PsA or AT pain.

Disclosures: This study was funded by a Glasgow (UK) Caledonian University-funded PhD studentship. The authors declared no conflicts of interest.

Source: Patience A, Steultjens M, Siebert S, Hendry G. Significant functional impairment and disability in individuals with psoriatic arthritis and Achilles tendon pain: A cross-sectional observational study. Rheumatol Int. 2024;44:1469-1479 (June 8). Doi: 10.1007/s00296-024-05629-x Source

Key clinical point: Patients with psoriatic arthritis (PsA) who did vs did not have Achilles tendon (AT) pain reported severe functional impairment and disability.

Major finding: Patients with PsA with vs without AT pain had significantly greater AT-related morning stiffness (90.9% vs 9.1%; P < .001), impaired AT function (median heel raise repetition rate 0.72 vs 1.24; P = .005), worse Psoriatic Arthritis Impact of Disease questionnaire score (mean 5.52 vs 3.38; P = .018), and pain on passive dorsiflexion (36.4% vs 0%; P = .011) and resisted plantarflexion (45.5% vs 0%; P = .003).

Study details: This cross-sectional, observational study included 22 patients with PsA with (n = 11) and without (n = 11) self-reported AT pain and 11 healthy individuals without PsA or AT pain.

Disclosures: This study was funded by a Glasgow (UK) Caledonian University-funded PhD studentship. The authors declared no conflicts of interest.

Source: Patience A, Steultjens M, Siebert S, Hendry G. Significant functional impairment and disability in individuals with psoriatic arthritis and Achilles tendon pain: A cross-sectional observational study. Rheumatol Int. 2024;44:1469-1479 (June 8). Doi: 10.1007/s00296-024-05629-x Source

Key clinical point: Patients with psoriatic arthritis (PsA) who did vs did not have Achilles tendon (AT) pain reported severe functional impairment and disability.

Major finding: Patients with PsA with vs without AT pain had significantly greater AT-related morning stiffness (90.9% vs 9.1%; P < .001), impaired AT function (median heel raise repetition rate 0.72 vs 1.24; P = .005), worse Psoriatic Arthritis Impact of Disease questionnaire score (mean 5.52 vs 3.38; P = .018), and pain on passive dorsiflexion (36.4% vs 0%; P = .011) and resisted plantarflexion (45.5% vs 0%; P = .003).

Study details: This cross-sectional, observational study included 22 patients with PsA with (n = 11) and without (n = 11) self-reported AT pain and 11 healthy individuals without PsA or AT pain.

Disclosures: This study was funded by a Glasgow (UK) Caledonian University-funded PhD studentship. The authors declared no conflicts of interest.

Source: Patience A, Steultjens M, Siebert S, Hendry G. Significant functional impairment and disability in individuals with psoriatic arthritis and Achilles tendon pain: A cross-sectional observational study. Rheumatol Int. 2024;44:1469-1479 (June 8). Doi: 10.1007/s00296-024-05629-x Source

Key clinical point: The risk of developing psoriatic arthritis (PsA) varied across different manifestations of psoriasis, with psoriasis vulgaris posing the highest risk.

Major finding: Compared with control individuals without psoriasis, patients with psoriasis vulgaris had the highest risk for incident PsA (hazard ratio [HR] 87.7; P < .0001), followed by those with generalized pustular psoriasis (HR 26.8; P < .0001) and pustulosis palmoplantaris (HR 15.3; P < .0001). The risk for PsA was marginally elevated in female vs male patients with psoriasis vulgaris (HR 1.1; P = .002).

Study details: This population-based retrospective cohort study included patients with psoriasis vulgaris (n = 35,281), pustulosis palmoplantaris (n = 9639), or generalized pustular psoriasis (n = 2281) who were propensity-score matched with an equal number of control individuals without psoriasis.

Disclosures: This study was funded by the Cluster of Excellence "Precision Medicine in Chronic Inflammation" (Deutsche Forschungsgemeinschaft) and other sources. Some authors declared having ties with various sources or serving as editorial board members for Frontiers.

Source: Gershater B, Bieber K, Vorobyev A, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: A sex- and ethnicity-specific analysis. Front Med. 2024;11:1385491 (June 20). Doi: 10.3389/fmed.2024.1385491 Source

Key clinical point: The risk of developing psoriatic arthritis (PsA) varied across different manifestations of psoriasis, with psoriasis vulgaris posing the highest risk.

Major finding: Compared with control individuals without psoriasis, patients with psoriasis vulgaris had the highest risk for incident PsA (hazard ratio [HR] 87.7; P < .0001), followed by those with generalized pustular psoriasis (HR 26.8; P < .0001) and pustulosis palmoplantaris (HR 15.3; P < .0001). The risk for PsA was marginally elevated in female vs male patients with psoriasis vulgaris (HR 1.1; P = .002).

Study details: This population-based retrospective cohort study included patients with psoriasis vulgaris (n = 35,281), pustulosis palmoplantaris (n = 9639), or generalized pustular psoriasis (n = 2281) who were propensity-score matched with an equal number of control individuals without psoriasis.

Disclosures: This study was funded by the Cluster of Excellence "Precision Medicine in Chronic Inflammation" (Deutsche Forschungsgemeinschaft) and other sources. Some authors declared having ties with various sources or serving as editorial board members for Frontiers.

Source: Gershater B, Bieber K, Vorobyev A, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: A sex- and ethnicity-specific analysis. Front Med. 2024;11:1385491 (June 20). Doi: 10.3389/fmed.2024.1385491 Source

Key clinical point: The risk of developing psoriatic arthritis (PsA) varied across different manifestations of psoriasis, with psoriasis vulgaris posing the highest risk.

Major finding: Compared with control individuals without psoriasis, patients with psoriasis vulgaris had the highest risk for incident PsA (hazard ratio [HR] 87.7; P < .0001), followed by those with generalized pustular psoriasis (HR 26.8; P < .0001) and pustulosis palmoplantaris (HR 15.3; P < .0001). The risk for PsA was marginally elevated in female vs male patients with psoriasis vulgaris (HR 1.1; P = .002).

Study details: This population-based retrospective cohort study included patients with psoriasis vulgaris (n = 35,281), pustulosis palmoplantaris (n = 9639), or generalized pustular psoriasis (n = 2281) who were propensity-score matched with an equal number of control individuals without psoriasis.

Disclosures: This study was funded by the Cluster of Excellence "Precision Medicine in Chronic Inflammation" (Deutsche Forschungsgemeinschaft) and other sources. Some authors declared having ties with various sources or serving as editorial board members for Frontiers.

Source: Gershater B, Bieber K, Vorobyev A, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: A sex- and ethnicity-specific analysis. Front Med. 2024;11:1385491 (June 20). Doi: 10.3389/fmed.2024.1385491 Source

Key clinical point: Patients diagnosed with psoriasis at an older vs younger age had a significantly shorter interval between psoriasis and psoriatic arthritis (PsA) diagnoses and also showed a higher likelihood of developing PsA within 6 months of having psoriasis.

Major finding: Patients with psoriasis onset at the age of 42.6 vs 18.9 years had a 62% shorter time interval between psoriasis and PsA diagnoses (exponentiated estimate 0.38; P < .001) and were ~4.6 times more likely to have a concurrent onset of PsA within 6 months of having psoriasis (odds ratio 4.56; P < .001).

Study details: This registry-based study included 384 patients diagnosed with PsA either after or concurrently with their psoriasis diagnosis.

Disclosures: This study was supported in part by a grant from the US National Institutes of Health. One author declared receiving payment or honoraria from and holding leadership or fiduciary roles with various sources.

Source: Cheemalavagu S, Jin Y, Husni ME. What clinical factors affect length of transition to psoriatic arthritis in patients with psoriasis? ACR Open Rheumatol. 2024 (June 28). Doi: 10.1002/acr2.11703 Source

Key clinical point: Patients diagnosed with psoriasis at an older vs younger age had a significantly shorter interval between psoriasis and psoriatic arthritis (PsA) diagnoses and also showed a higher likelihood of developing PsA within 6 months of having psoriasis.

Major finding: Patients with psoriasis onset at the age of 42.6 vs 18.9 years had a 62% shorter time interval between psoriasis and PsA diagnoses (exponentiated estimate 0.38; P < .001) and were ~4.6 times more likely to have a concurrent onset of PsA within 6 months of having psoriasis (odds ratio 4.56; P < .001).

Study details: This registry-based study included 384 patients diagnosed with PsA either after or concurrently with their psoriasis diagnosis.

Disclosures: This study was supported in part by a grant from the US National Institutes of Health. One author declared receiving payment or honoraria from and holding leadership or fiduciary roles with various sources.

Source: Cheemalavagu S, Jin Y, Husni ME. What clinical factors affect length of transition to psoriatic arthritis in patients with psoriasis? ACR Open Rheumatol. 2024 (June 28). Doi: 10.1002/acr2.11703 Source

Key clinical point: Patients diagnosed with psoriasis at an older vs younger age had a significantly shorter interval between psoriasis and psoriatic arthritis (PsA) diagnoses and also showed a higher likelihood of developing PsA within 6 months of having psoriasis.

Major finding: Patients with psoriasis onset at the age of 42.6 vs 18.9 years had a 62% shorter time interval between psoriasis and PsA diagnoses (exponentiated estimate 0.38; P < .001) and were ~4.6 times more likely to have a concurrent onset of PsA within 6 months of having psoriasis (odds ratio 4.56; P < .001).

Study details: This registry-based study included 384 patients diagnosed with PsA either after or concurrently with their psoriasis diagnosis.

Disclosures: This study was supported in part by a grant from the US National Institutes of Health. One author declared receiving payment or honoraria from and holding leadership or fiduciary roles with various sources.

Source: Cheemalavagu S, Jin Y, Husni ME. What clinical factors affect length of transition to psoriatic arthritis in patients with psoriasis? ACR Open Rheumatol. 2024 (June 28). Doi: 10.1002/acr2.11703 Source